Quest Diagnostics
614 hedge funds and large institutions have $12.1B invested in Quest Diagnostics in 2017 Q1 according to their latest regulatory filings, with 75 funds opening new positions, 197 increasing their positions, 230 reducing their positions, and 51 closing their positions.
80% more call options, than puts
Call options by funds: $18.2M | Put options by funds: $10.1M
47% more first-time investments, than exits
New positions opened: 75 | Existing positions closed: 51
7% more capital invested
Capital invested by funds: $11.2B → $12.1B (+$808M)
3% more funds holding
Funds holding: 598 → 614 (+16)
1% more ownership
Funds ownership: 88.35% → 89.35% (+1%)
14% less repeat investments, than reductions
Existing positions increased: 197 | Existing positions reduced: 230
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| 1 |
BlackRock
New York
|
+$1.41B |
| 2 |
Renaissance Technologies
New York
|
+$42.4M |
| 3 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$32.6M |
| 4 |
SCP
Seizert Capital Partners
Birmingham,
Michigan
|
+$30.6M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$30.2M |
Top Sellers
| 1 |
HM
HealthCor Management
New York
|
-$99.7M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$86.8M |
| 3 |
CIC
Crawford Investment Counsel
Atlanta,
Georgia
|
-$47.5M |
| 4 |
Allianz Asset Management
Munich,
Germany
|
-$35M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$22M |
DGX Hedge Fund Activity: Q1 2017 in Review
614 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Quest Diagnostics (DGX) for Q1 2017, worth a combined $12.1B — up 7.2% from $11.2B a quarter earlier.
Buyers outnumbered sellers: 75 funds opened new DGX positions and 51 closed out — a net gain of 24 holders — while 197 added to existing stakes and 230 trimmed.
The largest buyer was BlackRock, adding an estimated $1.41B. The largest seller was HealthCor Management, cutting an estimated $99.7M.
- 614 institutional investors held Quest Diagnostics (DGX) as of Q1 2017, up from 598 in Q4 2016.
- Funds reported $12.1B of Quest Diagnostics stock for Q1 2017, up 7.2% quarter-over-quarter.
- 75 funds opened new Quest Diagnostics positions in Q1 2017 and 51 closed out, a net change of +24 holders.
- The largest Quest Diagnostics buyer in Q1 2017 was BlackRock, an estimated $1.41B added.
- The largest Quest Diagnostics seller in Q1 2017 was HealthCor Management, an estimated $99.7M sold.
Based on aggregated 13F filings for Q1 2017.